A new inhaled treatment for chronic obstructive pulmonary disease (COPD)
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
This study is testing a new inhaled treatment called RB1000 to help people with COPD by reducing lung inflammation and improving breathing, while also keeping an eye on how it affects their overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alveolus Bio, INC. NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11041173 on NIH RePORTER |
What this research studies
This research focuses on developing a novel inhaled biotherapeutic called RB1000, designed to target inflammation in patients with chronic obstructive pulmonary disease (COPD). The treatment aims to address the underlying issues caused by an altered lung microbiome, which contributes to disease progression and acute exacerbations. By using a spray-dried powder formulation, the therapy seeks to improve lung function and reduce the frequency of symptom flare-ups. Patients will be monitored for changes in their condition and overall health status as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic obstructive pulmonary disease (COPD), particularly those experiencing frequent exacerbations.
Not a fit: Patients with mild or early-stage COPD who do not experience significant symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for COPD patients, potentially reducing symptoms and improving quality of life.
How similar studies have performed: While the approach of targeting the lung microbiome in COPD is relatively novel, previous studies have shown promise in using microbiome modulation for other chronic inflammatory conditions.
Where this research is happening
Birmingham, United States
- Alveolus Bio, INC. — Birmingham, United States (Active)
Researchers
- Principal investigator: Nicola, Teodora — Alveolus Bio, INC.
- Study coordinator: Nicola, Teodora
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.